Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates
Laura De Lellis, Serena Veschi, Nicola Tinari, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 3946-3946
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Drug repurposing for cancer therapy
Ying Xia, Ming Sun, Hai Huang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 99
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Antonino Glaviano, Hannah Lau, Lukas M. Carter, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 10
Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response
Stefanie Höfer, Larissa Frasch, Sarah Brajkovic, et al.
Molecular Systems Biology (2025)
Open Access | Times Cited: 1
Resveratrol Derivative Exhibits Marked Antiproliferative Actions, Affecting Stemness in Pancreatic Cancer Cells
Rosalba Florio, Barbara De Filippis, Serena Veschi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 1977-1977
Open Access | Times Cited: 13
Molecular Mechanisms of Chloroquine and Hydroxychloroquine Used in Cancer Therapy
Juan Bautista De Sanctis, Jaime Charris, Zuleyma Blanco, et al.
Anti-Cancer Agents in Medicinal Chemistry (2022) Vol. 23, Iss. 10, pp. 1122-1144
Closed Access | Times Cited: 19
The evidence for repurposing anti-epileptic drugs to target cancer
Mir Aroosa, Jonaid Ahmad Malik, Sakeel Ahmed, et al.
Molecular Biology Reports (2023) Vol. 50, Iss. 9, pp. 7667-7680
Open Access | Times Cited: 12
Metformin use and pancreatic ductal adenocarcinoma outcomes: a narrative review
D.H. Lee, Mun Sem Liew, Spiros Fourlanos, et al.
ANZ Journal of Surgery (2025)
Closed Access
Drug Repurposing in Pancreatic Cancer: A Multi-Stakeholder Perspective to Improve Treatment Options for Pancreatic Cancer Patients
Eric W. Hewitt, Gauthier Bouche, Alexandre Alencar, et al.
Cancer Management and Research (2025) Vol. Volume 17, pp. 429-440
Open Access
Niclosamide-Loaded Polyanhydride Nanoparticles to Combat Gemcitabine Resistance in Pancreatic Cancer
Brianna M. White, Venugopal Gunda, Susheel Kumar Nethi, et al.
Regenerative Engineering and Translational Medicine (2025)
Open Access
Repurposing Antiepileptic Drugs for Cancer: A Promising Therapeutic Strategy
Noor Tarawneh, S. A. Hussein, Shtaywy Abdalla
Journal of Clinical Medicine (2025) Vol. 14, Iss. 8, pp. 2673-2673
Open Access
Recent Advances and Challenges in the Treatment of Advanced Pancreatic Cancer: An Update on Completed and Ongoing Clinical Trials
Archana Shenoy, Amar Yousif, Muhammad Delwar Hussain
Cancers (2025) Vol. 17, Iss. 8, pp. 1319-1319
Open Access
Transcriptomics, metabolomics, and in-silico drug predictions for liver damage in young and aged burn victims
Beata Małachowska, Weng‐Lang Yang, Andrea C. Qualman, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 7
Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response
Stefanie Höfer, Larissa Frasch, Kerstin Putzker, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
Xavier Thuru, Romain Magnez, Hassiba El-Bouazzati, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3368-3368
Open Access | Times Cited: 11
Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies
Daniel Osei‐Bordom, Nikolaos Serifis, Zachary J. Brown, et al.
Surgical Oncology (2022) Vol. 43, pp. 101803-101803
Closed Access | Times Cited: 8
Structural Dynamics-Driven Discovery of Anticancer and Antimetastatic Effects of Diltiazem and Glibenclamide Targeting Urokinase Receptor
Yang Zhou, Meiru Song, Daoqing Xie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 8, pp. 5415-5426
Closed Access | Times Cited: 4
Drug Repurposing for Cancer Treatment: A Comprehensive Review
Abdulaziz H. Al Khzem, Mohamed S. Gomaa, Mansour S. Alturki, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 12441-12441
Open Access | Times Cited: 1
Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in 2D and 3D Cell Culture Models
Karabo Serala, Jinming Bai, Sharon Prince
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 23
Closed Access | Times Cited: 1
Unraveling new avenues in pancreatic cancer treatment: A comprehensive exploration of drug repurposing using transcriptomic data
Naina Sunildutt, Faheem Ahmed, Abdul Rahim Chethikkattuveli Salih, et al.
Computers in Biology and Medicine (2024) Vol. 185, pp. 109481-109481
Closed Access | Times Cited: 1
Advancement and recent trends in seeking less toxic and more active anti-cancer drugs: Insights into thiourea based molecules
Walaa Alharbi
Main Group Chemistry (2022) Vol. 21, Iss. 3, pp. 885-901
Closed Access | Times Cited: 7
Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies
James A. McCubrey, Stephen L. Abrams, Matilde Y. Follo, et al.
Advances in Biological Regulation (2022) Vol. 87, pp. 100917-100917
Open Access | Times Cited: 5
Pyrvinium Pamoate Enhances the Anti-cancer Activities of Gemcitabine in Pancreatic Cancer
Karabo Serala, Jinming Bai, Sharon Prince
(2024)
Open Access
Reprogramming tumor immune microenvironment by milbemycin oxime results in pancreatic tumor growth suppression and enhanced anti-PD-1 efficacy
Shreyas Gaikwad, Sanjay Srivastava
Molecular Therapy (2024) Vol. 32, Iss. 9, pp. 3145-3162
Closed Access
New targets for old drugs
Navanath Kumbhar, M.A. Aparna, Snehal K. Nimal, et al.
Elsevier eBooks (2023), pp. 315-349
Closed Access | Times Cited: 1
Drug Repositioning: A Monetary Stratagem to Discover a New Application of Drugs
Ankur Rohilla, Seema Rohilla
Current Drug Discovery Technologies (2023) Vol. 21, Iss. 1
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top